Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers
Abstract
Nonlive vaccine approaches that are simple to deliver and stable at room temperature or 2–8°C could be advantageous in controlling future Ebola virus (EBOV) outbreaks. Using an immunopotent DNA vaccine that generates protection from lethal EBOV challenge in small animals and nonhuman primates, we performed a clinical study to evaluate both intramuscular (IM) and novel intradermal (ID) DNA delivery.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Mar 19, 2019
- Source ID
- 10.1093/infdis/jiz132
Entities
People
- Albert J. Sylvester
- Ami Patel
- Christine C Roberts
- David B. Weiner
- Dawson Knoblock
- Dinah Amante
- Elisabeth Gillespie
- Gary P. Kobinger
- Jean Boyer
- Joel N Maslow
- Kate E. Broderick
- Kimberly A Kraynyak
- Mark Bagarazzi
- Matthew P Morrow
- Moonsup Jeong
- Niranjan Y. Sardesai
- Pablo Tebas
- Scott M White
- Trevor Mcmullan
- Trina Racine
- Young K Park
Organizations
- Defense Advanced Research Projects Agency
- Inovio Pharmaceuticals
- Laval University
- University of Pennsylvania
- W. W. Smith Charitable Trust
- Wistar Institute